EDGAR·FLOW

Zymeworks Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K — Neutral significance 48/100
What the filing says
Zymeworks' Board authorized a second 2026 share repurchase program of up to $200 million through 2028, with the company expecting to deploy $140 million of that authorization. As of November 11, 2026, the company had 68.7 million outstanding shares. Funding will come from existing balance sheet plus $55 million in expected Roche collaboration upfront fees and potential $100 million TRELEGY ELLIPTA milestone payment in Q1 2027.
Why this rating

Repurchase authorization of $140M expected deployment is ~22% of $649.5M market cap—meaningful but not transformational. Contingent on Roche deal and milestone achievements. Flexible program with no obligation. Moderate capital allocation signal.

View original filing on SEC.gov ↗ ZYME · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.